COVID-19 molecular test shipments exceed 150 million

The Advanced Medical Technology Association (AdvaMed) announced that total US shipments of COVID-19 molecular diagnostic tests have reached more than 150 million, based on the latest data from the association’s COVID-19 testing supply registry.

“COVID-19 testing is one of the main components of our country’s pandemic response, so increasing the supply of tests – and ensuring they reach the people who need them – is crucial,” said AdvaMed president and CEO Scott Whitaker.

“Our diagnostics manufacturers are meeting that challenge, working literally day and night to deliver more and more COVID tests and supplies. With more than 150 million tests shipped nationwide to date, and nearly 8.5 million tests shipped per week in August, up from 3.7 million weekly in April, we anticipate test manufacturers will ship between 32 and 35 million molecular tests in September. Add to that the more than 100 million antigen tests expected to be shipped by the end of fall, and it’s clear our industry is committed to meeting the demands of the COVID-19 crisis.”

Unveiled July 21, AdvaMed’s Registry compiles information from leading diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry.

The registry provides weekly state- and national-level updates on the number of molecular, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers and Thermo Fisher Scientific. – MB Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.